Galiximab

• CAT Number: I042421
• CAS Number: 357613-77-5
• Purity: ≥95%

Galiximab (Cat No.: I042421) is a chimeric (human-mouse) monoclonal antibody that targets CD80, a co-stimulatory molecule expressed on antigen-presenting cells and certain B-cell malignancies. By binding to CD80, galiximab interferes with T-cell activation and modulates immune responses, while also directly inhibiting the growth of CD80-positive tumor cells. It has been investigated in clinical trials, particularly for non-Hodgkin lymphoma, both alone and in combination with other therapies. Galiximab offers a targeted immunotherapeutic approach for modulating immune activity and treating B-cell-related cancers.

Reference

[1]. Smith SM, et, al. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma. 2013 Jul;54(7):1405-10.
[Content Brief]